Daniel Faga serves as the President, Chief Executive Officer, and Director at ANAPTYSBIO INC, a leading biotechnology company focused on developing novel antibody-based therapeutics for autoimmune and inflammatory diseases. With an extensive background in the biopharmaceutical industry, Faga brings a wealth of experience and leadership to his role at ANAPTYSBIO. Prior to joining the company, he held several key positions at other biotech firms, where he demonstrated a strong track record of driving growth and innovation. Faga's professional journey in the biotech sector began with his role as President and CEO at Ambit Biosciences, where he successfully led the company through its initial public offering and oversaw the development of several promising drug candidates. His strategic vision and ability to navigate complex scientific and business landscapes have been instrumental in advancing ANAPTYSBIO's mission to deliver transformative therapies to patients in need. Under his leadership, ANAPTYSBIO has made significant progress in its clinical pipeline, with several programs currently in various stages of development. As President and CEO, Faga is responsible for guiding the overall direction of ANAPTYSBIO, fostering a culture of scientific excellence, and ensuring the company's continued growth and success. His dedication to advancing innovative treatments for autoimmune and inflammatory diseases has positioned ANAPTYSBIO as a leader in the field. Faga's commitment to patients, combined with his extensive industry knowledge and leadership skills, make him an invaluable asset to the company and the broader biopharmaceutical community.